A Major Step in Malignant Melanoma Treatment from a Small Study

Malignant melanoma skin cancer treatment has advanced greatly in recent years. The most important advances concern stage 4, meaning metastatic disease. In conventional oncology treatment research, a new drug is first tested in stage 4 disease and compared with standard treatment. Scientific progress in malignant melanoma followed this same course.
When stage 4 malignant melanoma is diagnosed, patients are first assessed for a BRAF mutation. BRAF-positive patients receive drugs targeting it (vemurafenib, dabrafenib, trametinib, cobimetinib), while immunotherapies have come to the fore for BRAF-negative patients.
- Related topic: What is a BRAF mutation? In which cancers is BRAF positivity found?
BRAF mutations occur in approximately 50-70% of malignant melanomas and indicate both a potentially more aggressive disease course and a targeted drug target. Demonstration that a two-drug targeted combination significantly improves treatment success in BRAF-positive stage 4 melanoma raised the question of using BRAF-targeted drugs at earlier stages.
Standard treatment for stage 3 malignant melanoma is melanoma surgery followed by preventive (adjuvant) treatment (targeted drugs according to BRAF positivity, or immunotherapy). This study aimed to determine whether preoperative dual targeted treatment (dabrafenib and trametinib) improves disease outcomes over standard treatment in locally advanced stage 3 or oligometastatic malignant melanoma (with few metastases).
The 21 patients were assigned to two groups in a 1-to-2 ratio:
- One group (7 patients) received standard treatment: surgery followed by adjuvant treatment (52 weeks total),
- The other group (14 patients) received preoperative tumor-shrinking (neoadjuvant) treatment [8 weeks of 2 daily doses of dabrafenib (Tafinlar) 150 mg and 1 daily dose of trametinib (Mekinist) 2 mg as oral tablets], then surgery, followed by 44 weeks of adjuvant dabrafenib and trametinib (52 weeks / 1 year total)
- The primary study objective was to compare event-free survival. This was defined as no disease progression at month 12.
According to the study results:
- Because success in the experimental (neoadjuvant) treatment arm was very high, the study was stopped early to avoid harming the control arm.
- After a median follow-up of 18.6 months, median event-free survival was 19.7 months with neoadjuvant treatment versus 2.9 months with standard treatment.
- Neoadjuvant treatment was well tolerated and caused no severe (grade 4) side effects in any patient (rash, headache, fever and diarrhea were the most common side effects).
- In 2 patients, a pathological complete response was seen: the tumor specimen removed at surgery showed that preoperative (neoadjuvant) treatment had killed all tumor cells. Normally, targeted drugs shrink tumors and control disease rather than eliminate tumors completely.
The pathological complete responses are particularly noteworthy and will bring a different perspective to targeted drug use in malignant melanoma.
In conclusion, this study shows that starting treatment with BRAF-targeted drugs significantly improves outcomes in BRAF-positive locally advanced or oligometastatic malignant melanoma, even if surgery is possible at diagnosis. No overall survival difference has yet emerged, partly because of the small patient numbers. However, the marked difference in disease control duration is expected to translate into overall survival. Larger clinical trials will provide more comprehensive information about appropriate patient selection and pathological complete responses.
- Related topic: Success of dabrafenib and trametinib in BRAF-positive stage 4 lung cancer
Sources
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
Lancet Oncol 2018.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.